| BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer M Xing, WH Westra, RP Tufano, Y Cohen, E Rosenbaum, KJ Rhoden, ... The Journal of Clinical Endocrinology & Metabolism 90 (12), 6373-6379, 2005 | 1228 | 2005 |
| Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete … WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, ... Journal of clinical oncology 33 (1), 13, 2015 | 1072 | 2015 |
| Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis R Barroso-Sousa, WT Barry, AC Garrido-Castro, FS Hodi, L Min, IE Krop, ... JAMA oncology 4 (2), 173-182, 2018 | 971 | 2018 |
| Sacituzumab govitecan in metastatic triple-negative breast cancer A Bardia, SA Hurvitz, SM Tolaney, D Loirat, K Punie, M Oliveira, A Brufsky, ... New England journal of medicine 384 (16), 1529-1541, 2021 | 837 | 2021 |
| Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ... New England Journal of Medicine 372 (2), 134-141, 2015 | 807 | 2015 |
| Phase II trial of bicalutamide in patients with androgen receptor–positive, estrogen receptor–negative metastatic breast cancer A Gucalp, S Tolaney, SJ Isakoff, JN Ingle, MC Liu, LA Carey, K Blackwell, ... Clinical cancer research 19 (19), 5505-5512, 2013 | 806 | 2013 |
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ... Nature communications 8 (1), 1324, 2017 | 743 | 2017 |
| Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer A Bardia, IA Mayer, LT Vahdat, SM Tolaney, SJ Isakoff, JR Diamond, ... New England Journal of Medicine 380 (8), 741-751, 2019 | 728 | 2019 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 685 | 2019 |
| Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors A Patnaik, LS Rosen, SM Tolaney, AW Tolcher, JW Goldman, L Gandhi, ... Cancer discovery 6 (7), 740-753, 2016 | 662 | 2016 |
| MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer MN Dickler, SM Tolaney, HS Rugo, J Cortés, V Diéras, D Patt, H Wildiers, ... Clinical Cancer Research 23 (17), 5218-5224, 2017 | 633 | 2017 |
| ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆ A Gennari, F André, CH Barrios, J Cortes, E de Azambuja, A DeMichele, ... Annals of Oncology 32 (12), 1475-1495, 2021 | 607 | 2021 |
| Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE) SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... Journal of Clinical Oncology 38 (34), 3987-3998, 2020 | 602 | 2020 |
| HER2-low breast cancer: pathological and clinical landscape P Tarantino, E Hamilton, SM Tolaney, J Cortes, S Morganti, E Ferraro, ... Journal of Clinical Oncology 38 (17), 1951-1962, 2020 | 469 | 2020 |
| Endocrine toxicity of cancer immunotherapy targeting immune checkpoints LS Chang, R Barroso-Sousa, SM Tolaney, FS Hodi, UB Kaiser, L Min Endocrine reviews 40 (1), 17-65, 2019 | 451 | 2019 |
| Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors S Goel, Q Wang, AC Watt, SM Tolaney, DA Dillon, W Li, S Ramm, ... Cancer cell 29 (3), 255-269, 2016 | 427 | 2016 |
| Role of immunotherapy in triple-negative breast cancer TE Keenan, SM Tolaney Journal of the National Comprehensive Cancer Network 18 (4), 479-489, 2020 | 386 | 2020 |
| Efficacy and safety of anti-trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer A Bardia, IA Mayer, JR Diamond, RL Moroose, SJ Isakoff, AN Starodub, ... Journal of Clinical Oncology 35 (19), 2141, 2017 | 374 | 2017 |
| HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance S Pernas, SM Tolaney Therapeutic advances in medical oncology 11, 1758835919833519, 2019 | 332 | 2019 |
| Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ... JAMA oncology 5 (8), 1132-1140, 2019 | 331 | 2019 |
